Last $2.80 USD
Change Today +0.35 / 14.29%
Volume 54.6K
As of 12:44 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

volitionrx ltd (VNRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $3.25
52 Week Low
11/12/13 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VOLITIONRX LTD (VNRX)

Related News

No related news articles were found.

volitionrx ltd (VNRX) Related Businessweek News

No Related Businessweek News Found

volitionrx ltd (VNRX) Details

VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.

7 Employees
Last Reported Date: 04/28/14

volitionrx ltd (VNRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Medical Officer and Head of US Operatio...
Total Annual Compensation: --
Total Annual Compensation: --
Chief Scientific Officer of Belgian Volition ...
Total Annual Compensation: --
Chief Scientific Officer of Hypergenomics Pte...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

volitionrx ltd (VNRX) Key Developments

VolitionRX Ltd Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM

VolitionRX Ltd Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Cameron Reynolds, Chief Executive Officer, President and Director.

VolitionRX Ltd Invests in Laboratory Automation System to Increase Throughput Capacity

VolitionRx Limited announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory. The Tecan EVO200 is a robot that will significantly accelerate VolitionRx's large scale clinical studies by increasing the throughput and rate of blood sample analysis by up to five times that of the current manual methods. Initially the robot will be used in a stand-alone mode but Volition is in the process of establishing a Laboratory Information Management System (LIMS) which will integrate the robot into a wider laboratory automation system. This will provide a seamless workflow incorporating blood sample recognition, testing, data capture, and quality control as part of a quality management system. Installation of the robot is particularly significant as the company announced an increase of 3,000 (from 11,000 to 14,000) in the number of prospective blood samples to be included in its on-going colorectal cancer clinical trial, which is jointly sponsored by VolitionRx and the University of Copenhagen.

VolitionRX Limited Announces Executive Changes

On July 1, 2014, Malcolm Lewin resigned from his positions as Chief Financial Officer and Treasurer of VolitionRX Limited. On July 1, 2014, Mike O'Connell was appointed as Chief Financial Officer and Treasurer of the company to serve until his successor is duly appointed. On July 1, 2014, Mr. O'Connell accepted such appointment. Mike O'Connell is presently the CEO of Isosceles. Mr. O'Connell was appointed to serve a Chief Financial Officer and Treasurer because of his extensive financial and accounting knowledge.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNRX:US $2.80 USD +0.35

VNRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation VNRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLITIONRX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at